(Q46750954)

English

Effect of 24-week treatment with telmisartan on myocardial structure and function: relationship to insertion/deletion polymorphism of the angiotensin-converting enzyme gene

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16222898

Effect of 24-week treatment with telmisartan on myocardial structure and function: relationship to insertion/deletion polymorphism of the angiotensin-converting enzyme gene (English)

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16222898

author name string

A O Conrady

1

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16222898

I O Kiselev

2

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16222898

N I Usachev

3

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16222898

A N Krutikov

4

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16222898

O I Yakovleva

5

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16222898

E V Polunicheva

6

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16222898

O A Ovchinnikova

7

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16222898

A V Panov

8

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16222898

publication date

1 January 2005

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16222898

Journal of International Medical Research

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16222898

33 Suppl 1

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16222898

30A-38A

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16222898

The past, present and future of hypertension management: a potential role for AT(1)-receptor antagonists

1 reference

https://api.crossref.org/works/10.1177%2F14732300050330S105

21 January 2018

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

1 reference

https://api.crossref.org/works/10.1177%2F14732300050330S105

21 January 2018

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

1 reference

https://api.crossref.org/works/10.1177%2F14732300050330S105

21 January 2018

Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect

1 reference

https://api.crossref.org/works/10.1177%2F14732300050330S105

21 January 2018

Preventing renal complications in diabetic patients: the Diabetics Exposed to Telmisartan And enalaprIL (DETAIL) study

1 reference

https://api.crossref.org/works/10.1177%2F14732300050330S105

21 January 2018

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

1 reference

https://api.crossref.org/works/10.1177%2F14732300050330S105

21 January 2018

Left ventricular hypertrophy as a surrogate end-point in hypertension

1 reference

https://api.crossref.org/works/10.1177%2F14732300050330S105

21 January 2018

New aspects on angiotensin-converting enzyme: from gene to disease

1 reference

https://api.crossref.org/works/10.1177%2F14732300050330S105

21 January 2018

Association between angiotensin-converting enzyme gene polymorphisms and regression of left ventricular hypertrophy in patients treated with angiotensin-converting enzyme inhibitors.

1 reference

https://api.crossref.org/works/10.1177%2F14732300050330S105

21 January 2018

Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method

1 reference

https://api.crossref.org/works/10.1177%2F14732300050330S105

21 January 2018

Hypertensive left ventricular hypertrophy: pathophysiological and clinical issues

1 reference

https://api.crossref.org/works/10.1177%2F14732300050330S105

21 January 2018

Are all antihypertensive drug classes equal in reducing left ventricular hypertrophy?

1 reference

https://api.crossref.org/works/10.1177%2F14732300050330S105

21 January 2018

Comparative effects of candesartan and enalapril on left ventricular hypertrophy in patients with essential hypertension: the candesartan assessment in the treatment of cardiac hypertrophy (CATCH) study.

1 reference

https://api.crossref.org/works/10.1177%2F14732300050330S105

21 January 2018

Reduction of cardiac hypertrophy in TGR(mREN2)27 by angiotensin II receptor blockade

1 reference

https://api.crossref.org/works/10.1177%2F14732300050330S105

21 January 2018

Effects of AT1 receptor blockade on blood pressure and the renin-angiotensin system in spontaneously hypertensive rats of the stroke prone strain

1 reference

https://api.crossref.org/works/10.1177%2F14732300050330S105

21 January 2018

Comparative antihypertensive and renoprotective effects of telmisartan and lisinopril after long-term treatment in hypertensive diabetic rats

1 reference

https://api.crossref.org/works/10.1177%2F14732300050330S105

21 January 2018

Freehand three-dimensional echocardiographic evaluation of the effect of telmisartan compared with hydrochlorothiazide on left ventricular mass in hypertensive patients with mild-to-moderate hypertension: a multicentre study

1 reference

https://api.crossref.org/works/10.1177%2F14732300050330S105

21 January 2018

Angiotensin II receptor blocker telmisartan: effect on blood pressure profile and left ventricular hypertrophy in patients with arterial hypertension

1 reference

https://api.crossref.org/works/10.1177%2F14732300050330S105

21 January 2018

Regression of left ventricular hypertrophy and improvement of diastolic function in hypertensive patients treated with telmisartan

1 reference

https://api.crossref.org/works/10.1177%2F14732300050330S105

21 January 2018

Effects of telmisartan and losartan on left ventricular mass in mild-to-moderate hypertension. A randomized, double-blind trial

1 reference

https://api.crossref.org/works/10.1177%2F14732300050330S105

21 January 2018

Effects of the angiotensin II receptor blockers telmisartan versus valsartan on the circadian variation of blood pressure: impact on the early morning period

1 reference

https://api.crossref.org/works/10.1177%2F14732300050330S105

21 January 2018

Ventricular and vascular remodelling effects of the angiotensin II receptor blocker telmisartan and/or the angiotensin-converting enzyme inhibitor ramipril in hypertensive patients

1 reference

https://api.crossref.org/works/10.1177%2F14732300050330S105

21 January 2018

An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels

1 reference

https://api.crossref.org/works/10.1177%2F14732300050330S105

21 January 2018

Identifiers

10.1177/14732300050330S105

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16222898

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16222898

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46750954&oldid=2129824583"